Montelucaste Chesmon (Montelukast)

Montelukast, the active ingredient in Montelucaste Chesmon, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in patients requiring controller therapy.

GNH USA supplies Montelucaste Chesmon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable supply chains, comprehensive documentation, and responsive technical support.

Montelukast is a leukotriene receptor antagonist used to treat conditions driven by cysteinyl leukotriene–mediated inflammation.

- Asthma: improves long‑term control and reduces the frequency of wheezing episodes. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness that may or may not lead to vomiting. - Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that can impair breathing. - Mood changes: including agitation, depression or suicidal thoughts. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes. - Severe allergic reaction: rash, hives, or anaphylaxis requiring immediate medical care.

When prescribing Montelucaste Chesmon, clinicians should consider several safety and handling measures. - Assess patient history: confirm diagnosis of asthma or allergic rhinitis before initiating therapy. - Monitor psychiatric symptoms: watch for mood alterations, depression or suicidal ideation. - Evaluate liver function: consider baseline tests in patients with known hepatic disease. - Use caution in children: adjust monitoring as pediatric safety data are limited. - Store at room temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Montelukast can interact with other medicines, and the significance of these interactions varies.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations, raising risk of adverse effects. - Phenobarbital: can reduce montelukast levels, potentially diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Fluconazole: may modestly elevate montelukast exposure; monitor for side effects. - Carbamazepine: may lower montelukast concentrations; assess clinical response. - Warfarin: occasional reports of altered INR; check coagulation status periodically.